BNR News and Press, Burning Rock Biotech Limited From 03/28/23

GUANGZHOU, China, March 28, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today ...

GUANGZHOU, China, March 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today ...

GUANGZHOU, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today a...

China-based biotech Burning Rock Biotech Limited ( NASDAQ: BNR ) added ~9% in the morning hours Tuesday after announcing that the FDA issued its Breakthrough Device Designation for the company’s multi-cancer detection test OverC. The blood-based test is designed for the ear...

IRVINE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been grant...

Summary Burning Rock Biotech went public in mid-2020, raising approximately $248 million in gross proceeds in an IPO and private placement. The company provides a variety of cancer screening test capabilities in China. BNR has reduced forward growth guidance, but I fear the sharp ri...

Burning Rock Biotech Limited (BNR) Q3 2022 Earnings Conference Call November 16, 2022 08:30 A.M. ET Company Participants Yusheng Han - Chairman and CEO Dr. Shaokun Chuai - COO Leo Li - CFO Conference Call Participants Alexis Yan - Morgan Stanley M...

The following slide deck was published by Burning Rock Biotech Limited in conjunction with their 2022 Q3 earnings call. For further details see: Burning Rock Biotech Limited 2022 Q3 - Results - Earnings Call Presentation

Burning Rock Biotech press release ( NASDAQ: BNR ): Q3 GAAP EPS of -$0.31 beats by $0.03 . Revenue of $21.74M (+22.1% Y/Y) misses by $0.32M . Non-GAAP gross margin was 75.7% for the three months ended September 30, 2022, compared to 73.4% for the same peri...

GUANGZHOU, China, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, t...